ArticleBreast cancer research : BCR2018

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.

Jennifer D Brooks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.